Precigen Stock Gets Stronger EPS Forecast from HC Wainwright

Precigen, Inc. (NASDAQ:PGEN) – Equities researchers at HC Wainwright lifted their FY2026 earnings estimates for Precigen in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings of $0.24 per share for the year, up from their prior estimate of $0.14. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Precigen’s FY2027 earnings at $0.65 EPS.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. The firm had revenue of $74.15 million for the quarter, compared to analyst estimates of $71.55 million. Precigen had a net margin of 15.55% and a return on equity of 57.93%. The company’s quarterly revenue was up 2437.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.06) earnings per share.

A number of other brokerages have also recently issued reports on PGEN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a report on Thursday, October 15th. B. Riley Financial initiated coverage on Precigen in a report on Friday, September 25th. They set a “buy” rating and a $12.00 price target for the company. Citigroup reiterated a “market outperform” rating on shares of Precigen in a report on Thursday, November 5th. Wall Street Zen raised Precigen from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Finally, Zacks Research lowered Precigen from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 5th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.50.

Precigen Stock Performance

Shares of PGEN opened at $4.52 on Monday. The company has a market cap of $1.62 billion, a PE ratio of 45.20 and a beta of 1.01. The firm has a 50-day moving average of $6.88 and a 200-day moving average of $5.28. Precigen has a one year low of $3.04 and a one year high of $8.98. The company has a debt-to-equity ratio of 1.12, a current ratio of 5.58 and a quick ratio of 4.83.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Carolina Wealth Advisors LLC acquired a new stake in Precigen during the third quarter worth approximately $46,000. USA Financial Formulas bought a new stake in shares of Precigen during the third quarter worth approximately $52,000. Sterling Capital Management LLC grew its position in shares of Precigen by 847.8% in the third quarter. Sterling Capital Management LLC now owns 6,426 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 5,748 shares during the last quarter. State of Wyoming acquired a new position in shares of Precigen in the first quarter valued at approximately $27,000. Finally, Royal Bank of Canada grew its position in shares of Precigen by 102.6% in the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,426 shares during the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Insider Buying and Selling at Precigen

In other news, COO Rutul R. Shah sold 34,658 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $7.50, for a total value of $259,935.00. Following the transaction, the chief operating officer directly owned 465,012 shares of the company’s stock, valued at $3,487,590. This represents a 6.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey B. Kindler sold 185,000 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the sale, the director owned 17,100 shares of the company’s stock, valued at approximately $127,224. This represents a 91.54% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 235,000 shares of company stock worth $1,751,400. Corporate insiders own 41.40% of the company’s stock.

Precigen Company Profile

Precigen, Inc. is a biotechnology company focused on developing gene and cell therapies, including engineered immunotherapies. The company is based in Germantown, Maryland, and its roots include Intrexon, which adopted the Precigen name in 2020. Its approved product, PAPZIMEOS (zopapogene imadenovec-drba), is a gene therapy for adults with recurrent respiratory papillomatosis, a rare condition associated with human papillomavirus types 6 and 11. Precigen is also developing investigational therapies for cancers and other diseases.